Monday, April 21, 2025

Dual-drug therapy shows promise for treating alcohol use disorder

Date:

Share post:

New York, July 31 : A team of researchers has leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side-effects or complications associated with current treatment regimens.

The study, published in the journal Nature Communications, indicates that the approach had highly successful results in mice and may apply to other drugs that are often abused.

“Alcohol use disorder is really a process of maladapted learning and memory,” said researcher Dorit Ron from the University of California, San Francisco.

“Alcohol is rewarding, and we learn to associate alcohol, and even the environment in which we drink the alcohol, with that reward,” Ron added.

At the root of the team’s thinking is the idea that AUD and other substance abuse disorders are the results of reinforced pathways in the brain, and that those pathways can be blocked or redirected, ending cravings and habitual behaviour.

The researcher said she is studying the role of the enzyme mTORC1 in the creation of those memories and associations, to create an effective drug that can treat the neurological causes of AUD.

Ordinarily, mTORC1 is involved in brain plasticity, helping to create connections between neurons that reinforce memory. In previous work, Ron showed that consuming alcohol activates the enzyme in the brain.

Ron has also shown that blocking the activity of mTORC1 with the FDA-approved compound rapamycin, used to treat some types of cancer and suppress the immune response in transplant patients, can halt cravings in mice engineered for alcohol use disorder.

But mTORC1 contributes to a bevy of other bodily tasks related to metabolism and liver function, and people taking it for an extended period often develop liver toxicity, glucose intolerance, and other side effects.

Ron believes that tackling addiction from a neurological perspective has potential for broad applications.

“We could see these side effects in mice who are taking rapamycin or RapaLink-1, and then when you give Rapablock, it’s like magic, the side effects are gone,” Ron noted.(IANS)

Related articles

Pope Francis leaves world and faithful in times of conflict

Rome, April 21: "Dearest brothers and sisters, with deep sorrow I must announce the death of our Holy...

Sensex jumps 855 points, Nifty ends above 24,100; banks, IT lead rally

Mumbai, April 21: The Indian stock market continued its strong rally for the fifth day in a row...

Gold hits new record high of Rs 96,805, may touch Rs 1 lakh mark soon

New Delhi, April 21: Gold prices in India touched a new record high of Rs 96,805 per 10...

Manipur Police arrest 8 militants, rescue three women

Imphal, April 21: Manipur Police arrested eight more militants belonging to Kangleipak Communist Party(People’s War Group) and rescued...